You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 386 Phase I/Ib first-in-human study of HEK-NIZ985, a recombinant IL-15/IL-15Rα heterodimer, alone and in combination with spartalizumab, in adults with advanced and metastatic solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
386 Phase I/Ib first-in-human study of HEK-NIZ985, a recombinant IL-15/IL-15Rα heterodimer, alone and in combination with spartalizumab, in adults with advanced and metastatic solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2020 to March 2024

AbstractFullPdf
Nov 2020406054
Dec 20206109
Jan 202161012
Feb 20216608
Mar 2021128019
Apr 202182010
May 202121018
Jun 20210028
Jul 20210016
Aug 20210012
Sep 20210012
Oct 202166014
Nov 2021138032
Dec 20218005
Jan 20223804
Feb 202238016
Mar 202264012
Apr 20224006
May 20227609
Jun 2022116026
Jul 20223808
Aug 202266013
Sep 20224205
Oct 20223602
Nov 20224206
Dec 20222200
Jan 20234003
Feb 20234404
Mar 20232805
Apr 20232404
May 20233006
Jun 20232400
Jul 20232606
Aug 20232605
Sep 20235002
Oct 202311508
Nov 20237005
Dec 20235402
Jan 20241000
Feb 20246404
Mar 20242200
Total23540410